Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab ... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... और पढ़ें
Singapore, April 27 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... और पढ़ें